Technology

Nordic Bioscience’s ProteinFingerPrint Technology™ is backed by more than 30 years of research and used by world-leading pharmaceutical companies. Our extracellular matrix-based approach quantifies disease activity with precision unmatched by omics providers, offering mechanistic and pharmacodynamic insights into tissue remodeling, a process crucial to understand when evaluating the effect of a therapeutic Intervention.

The RheumaTrace™ biomarker panel for rheumatological diseases (RMDs) has been developed based on 3 decades of research and more than 200 peer-reviewed publications.

The panel comprises seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics. Together, these biomarkers offer researchers and drug developers invaluable insights into disease activity, the trajectory of disease progression, and the efficacy of therapeutic interventions.

NordicPRO‑C3™ is a highly reliable and precise biomarker assay that measures active fibrosis by detecting the formation of type III collagen – a key driver of fibrogenesis across major organs, including the liver, lungs, kidneys, heart, intestines, and skin.

NordicPRO-C3™ provides a powerful tool for monitoring treatment efficacy and tracking disease progression over time. Furthermore, it serves as a critical decision-making tool in clinical trials, helping researchers assess treatment impact, understand the mechanism of action, and accelerate drug development.

The Nordic Bioscience laboratory services are performed in compliance with international standards for GCP and GLP. Our operations are accredited by the College of American Pathologists (CAP). We have a long history of measuring and providing clinical data used by decision-makers to make vital decisions.

Our laboratory has the capacity to provide customized solutions. We have scientific biomarker experts, experienced project managers, and high-quality equipment to handle, plan and execute biomarker strategies across many levels in any organization – no project is too little, and no organization is too big.